Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
News for COSMO PHARMA NV ORD (CMOPF) centers on the activities of Cosmo Pharmaceuticals N.V., a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and CDMO. Company announcements highlight how Cosmo executes its Vision 2030 strategy, emphasizing recurring revenue growth, AI-enabled medical technologies, and global expansion of its dermatology and GI franchises.
Investors following CMOPF-related news can expect updates on GI Genius™ and the ColonPRO / ColonPRO EU AI platforms for colonoscopy, including regulatory milestones such as CE certification in Europe and clinical evidence from international trials. News also covers the evolution of GI Genius™ into a scalable AI platform, deployment across clinical sites, and initiatives such as spatial-computing usability studies that integrate AI endoscopy modules with advanced visualization devices.
Dermatology news frequently focuses on Winlevi® and clascoterone 5% topical solution. Releases describe new regulatory approvals for Winlevi® in regions including the European Union, South Korea, Brazil, and other territories, as well as commercialization through partners. For clascoterone 5% solution in male androgenetic alopecia, news has detailed Phase III topline results, patient-reported outcomes, safety data, and plans for regulatory submissions in the United States and Europe.
Additional updates include progress in clinical programs for bile acid diarrhea and distal ulcerative colitis, renewal of manufacturing agreements such as the multi-year supply arrangement with Takeda for Mesalazine MMX 1200 mg, and financial communications on revenue mix, recurring revenue trends, and cash position. Bookmark this page to monitor regulatory events, clinical milestones, partnership announcements, and financial disclosures that relate to CMOPF and Cosmo Pharmaceuticals’ multi-platform growth strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cosmo Pharmaceuticals N.V. invites stakeholders to a Q&A session on May 4, 2021, discussing its FDA-approved AI device, GI Genius™, designed for detecting colon cancer. This technology, also approved in Europe, Australia, Israel, and the UAE, is distributed globally through a partnership with Medtronic. Key representatives, including CEO Alessandro Della Chà and CFO Niall Donnelly, will explain how GI Genius™ addresses colorectal cancer challenges. The company focuses on gastrointestinal disorders and has partnerships for product distribution.
Cosmo Pharmaceuticals has received FDA approval for its GI Genius™ intelligent endoscopy system, a groundbreaking device designed for detecting lesions during colonoscopy. This marks a significant achievement after over a decade of research, as it is the first device of its kind to achieve approval via the De Novo application. The system operates in real-time, improving detection rates of precancerous lesions and is compatible with all endoscopes. Cosmo has partnered with Medtronic for worldwide distribution, aiming at a market potential worth at least $1.1 billion.
Cosmo Pharmaceuticals N.V. reported a return to operating profit in 2020, with revenues of €60.9 million, slightly down from €62.5 million in 2019. The company achieved a €6.9 million operating profit, compared to a €12.3 million loss the previous year. Net expenses dropped significantly to €54 million from €74.8 million. Despite a net loss after tax of €7.9 million, improved cash flow and significant equity stakes position Cosmo favorably, holding €212.9 million in cash. The 2021 outlook anticipates revenues between €60 million and €64 million, contingent on FDA approval for GI Genius™.
Cosmo Pharmaceuticals NV (SIX: COPN) will hold a telephone conference on March 26, 2021, at 2:00 PM CET to discuss its 2020 financial results and 2021 outlook. CEO Alessandro Della Chà and CFO Niall Donnelly will present during this session. Dial-in numbers are provided for participants from Switzerland, the UK, and the US. The presentation materials will be available on the company's website from 7:00 AM CET on the same day. Cosmo focuses on developing products for gastrointestinal disorders and has partnered with Medtronic for its AI device.